Stop Gliptins in Patients Admitted With Heart Failure

See updated information from the FDA concerning heart failure risk with saxagliptin and alogliptin

You'll see new warnings about a possible increased risk of heart failure with saxagliptin (Onglyza, etc) and alogliptin (Nesina, etc).

So far, saxagliptin has the strongest evidence. There's one heart failure hospitalization for every 143 patients treated with saxagliptin over 2 years.

Alogliptin seems less likely to be linked to heart failure...sitagliptin (Januvia) doesn't seem to be a problem...and it's too early to say if linagliptin (Tradjenta) increases risk.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals